Drug Shortage Report for VAQTA
Report ID | 178347 |
Drug Identification Number | 02229702 |
Brand name | VAQTA |
Common or Proper name | hepatitis A vaccine, purified inactivated Suspension for injection |
Company Name | MERCK CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | HEPATITIS A VACCINE, INACTIVATED |
Strength(s) | 50UNIT |
Dosage form(s) | SUSPENSION |
Route of administration | INTRAMUSCULAR INTRAMUSCULAR |
Packaging size | 50U/1ML 1DOSE VIAL |
ATC code | J07BC |
ATC description | VIRAL VACCINES |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2022-12-14 |
Estimated end date | 2023-03-10 |
Actual end date | 2023-02-21 |
Shortage status | Resolved |
Updated date | 2023-02-22 |
Company comments | Remaining doses are reserved for the public immunization program. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 16750 ROUTE TRANSCANADIENNE KIRKLAND, QUEBEC CANADA H9H 4M7 |
Company contact information | 1-800-567-2594 medinfocanada@merck.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2023-02-22 | English | Compare |
v5 | 2023-02-21 | French | Compare |
v4 | 2023-02-21 | English | Compare |
v3 | 2022-12-15 | English | Compare |
v2 | 2022-12-14 | French | Compare |
v1 | 2022-12-14 | English | Compare |
Showing 1 to 6 of 6